عنوان انگلیسی مقاله:
ترجمه فارسی عنوان مقاله:
Sciencedirect - Elsevier - Surgical Oncology Clinics of NA, 29 (2020) 87-103: doi:10:1016/j:soc:2019:08:007
Laura Cristoferi, MDa, Alessandra Nardi, PhDb, Pietro Invernizzi, MD, PhDa, George Mells, MRCP, PhDc, Marco Carbone, MD, PhDa,d
The forthcoming availability of several novel drugs in primary biliary cholangitis (PBC)
coupled with the rise of high-throughput omics technologies prompt changing the paradigm
of the management of the disease.
Precision medicine (PM), through the application of omics-based approaches, should enable
identifying disease variants, stratifying patients according to disease trajectory, risk of disease
progression, and likelihood of response to different therapeutic options in PBC.
The development of PM needs specific interventions, such as sequencing more genomes,
creating bigger biobanks, and linking biological information to health data in electronic
The authors envisage that a diagnostic work-up of PBC patients will include information
on genetic variants and molecular signature that may define a particular subtype of disease
and provide an estimate of treatment response and survival
KEYWORDS : Primary biliary cholangitis | Precision medicine | Risk-stratification | Autoimmune liver disease | Individualized care | Novel therapies | Omics